Vollenweider Hasler

Fakultäten » Medizinische Fakultät » Psychiatrische Universitätsklinik » Psychiatrie, Psychotherapie und Psychosomatik, Klinik für » Prof. Dr. F. X. Vollenweider » Vollenweider Hasler

Completed research project

Title / Titel Serotonin 5-HT2A receptor dynamics in ASC
PDF Abstract (PDF, 14 KB)
Summary / Zusammenfassung Serotonergic (5-hydroxytryptamine; 5-HT) mechanisms have been implicated
in a number of physiological and pathophysiological processes including mood,
anxiety, and cognitive functioning. Among the many 5-HT receptor subtypes,
the 5-HT2A receptors (5-HT2A-R) seem to be of particular importance in
mediating these effects, and they are prime targets for a variety of psychoactive
substances—from hallucinogenic drugs, through atypical antipsychotics, to
anxiolytics and antidepressants. A significant downmodulation of 5-HT2A-R in prefrontal and limbic structures was reported in animals after a singel dose of LSD, psilobin or DOI (Buckholz Gresh et al. 2005, Cohen 2005) and associated with the improvementof anxiety in clinical studies with hallicinogens (Vollenweider and Kometer 2010). Wheter hallucinogenic 5-HT2A agonsits such as pslicolybi reduce 5-HT2A-R density is not known.

This study aims at investigating the effcet of a single dose of psilcybin on brain 5-HT2A receptor density in normal subjects unsig 18F-Altanserin PET. The potential effects of 5-HT2A receptor downmodulation on cognitive performance after 6 and 24 h after treatment with psilocybin shall be assessed using a set of the CANATAB test battery. The stud shall help to elucidate further the role of 5-HT2A-R in cognitive performance in health and desease.
Publications / Publikationen Hasler F, Kuznetsova OF, Krasikova RN, Cservenyak T, Quednow BB, Vollenweider FX, Ametamey SM, Westera G (2009): GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. Appl. Radiat. Isot. 67: 598-601.
Keywords / Suchbegriffe 5-HT2A, tolerance, psilocybin, 18F-Altanserin, PET
Project leadership and contacts /
Projektleitung und Kontakte
Prof. F.X. Vollenweider (Project Leader)
Dr. F. Hasler (Project Leader)  
Prof. B. Quednow  
Funding source(s) /
Unterstützt durch
SNF (Personen- und Projektförderung), Foundation
HRC (2013)
In collaboration with /
In Zusammenarbeit mit
Prof. G. Schubiger, Center for Pharmaceutical Sciences, ETH und University of Zürich Switzerland
Duration of Project / Projektdauer Jun 2009 to Jul 2013